

# Developmental Therapeutics

## RESEARCH PROGRAM

**Friday, May 15, 2020**

1:00 p.m. - 2:00 p.m.

Zoom Meeting

***“Single Arm Neoadjuvant Phase I/II Study of  
MEDI4736 (anti-PD-L1 antibody) Concomitant  
with Weekly Nab-paclitaxel and Dose-dense  
Doxorubicin/cyclophosphamide (ddAC)  
Chemotherapy for Clinical Stage I-III Triple  
Negative Breast Cancer (TNBC)”***

**Kim Blenman**

Associate Research Scientist, Medical Oncology